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As the global epidemic of diabetes con-
tinues to rise, the need for effective
diabetes self-management education
also continues to increase. Self-
management education is a necessary
component of diabetes prevention
and care because outcomes are highly
dependent on the daily efforts and
decisions made by people with 
diabetes and those at risk. 
There is a growing number of
studies demonstrating both the effec-
tiveness of education for improving
outcomes1–7 and its cost-effective-
ness.8 However, with the current
emphasis on cost-efficiencies, the
resources to provide diabetes educa-
tion are threatened in many places
around the world. We cannot assume
that other health professionals, insur-
ance providers and health ministries
will continue to provide the necessary
support for diabetes education unless
we are able to document its effective-
ness at a local and national level.
Standards for diabetes self-manage-
ment education9 are calling for better
documentation about the effects 
of diabetes education on the know l-
edge, behavioural and psychosocial
domains. A variety of valid and reliable
instruments for measuring these out-
comes are available,10 particularly in
European and other developed coun-
tries. Although it is tempting to create
a programme-specific instrument or to
simply translate standardised instru-
ments, this approach will not provide
the level of evidence needed to ensure
financial and other support for educa-
tion in many countries. Standardised
instruments cannot be reliably used in
different countries until they are vali-
dated among the target population.
Validation is necessary to ensure con-
sistency of understanding, language,
culture and literacy. 
In this issue of Practical Diabetes
International (p 238), Al-Qazaz et al.
report on the translation and valida-
tion of one standardised instrument,
the Diabetes Knowledge Test (DKT).11
Although the DKT evaluates only one
of the domains that needs to be meas-
ured, this paper by Al-Qazaz et al.
provides an excellent model for the
translation and validation process that
can be used for other instruments.
This represents a significant effort;
nevertheless, it is essential if we 
are going to be able to continue to
make available and provide diabetes
self-management education for the
millions in need.
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HUMULIN* VIAL, CARTRIDGE, PEN, AND KWIKPEN
HUMULIN IS HUMAN INSULIN (PRB)
Presentation Humulin S is a sterile solution of 100IU/ml human insulin available as either
10ml vial or 3ml cartridge. Humulin I is a sterile suspension of 100IU/ml isophane human
insulin available as either 10ml vial, 3ml cartridge, 3ml Pen, or 3ml KwikPen. Humulin
M3 is a sterile suspension of 100IU/ml human insulin in the proportion of 30% soluble
insulin and 70% isophane insulin available as either 10ml vial, 3ml cartridge, 3ml Pen,
or 3ml KwikPen. Uses For the treatment of patients with diabetes mellitus who require
insulin for the maintenance of glucose homeostasis. Dosage and Administration
All Humulin preparations should be given by subcutaneous injection. Only Humulin S
may be given intravenously. Resuspension Humulin S does not require resuspension.
Humulin I and Humulin M3 require resuspension immediately before use. Please see
Summaries of Product Characteristics or Patient Information Leaflets for details on how
to do this. Mixing of insulins (vials only): Humulin S may be administered in combination
with Humulin I. The shorter-acting insulin (Humulin S) should be drawn into the syringe
first, to prevent contamination of the vial by the longer-acting preparation (Humulin I). It is
advisable to inject immediately after mixing.
Prices (Humulin)
£15.68 - 1 X 10ml vials Humulin S
£19.08 - 5 X 3ml cartridges Humulin S
£15.68 - 1 X 10ml vials Humulin I
£19.08 - 5 X 3ml cartridges Humulin I
£28.44 - 5 X 3ml Humulin I Pens
£21.70 - 5 X 3ml Humulin I KwikPens
£15.68 - 1 X 10ml vials Humulin M3
£19.08 - 5 X 3ml cartridges Humulin M3
£28.44 - 5 X 3ml Humulin M3 Pens
£21.70 - 5 X 3ml Humulin M3 KwikPens
Product Licence Numbers
Humulin S: 00006/0216 and 0242
Humulin I: 00006/0228 and 0257
Humulin M3: 00006/0233 and 0260
Humulin I Pen: 00006/0338
Humulin I KwikPen: 00006/0338
Humulin M3 Pen: 00006/0341
Humulin M3 KwikPen: 00006/0341
*HUMULIN (human insulin [prb]) is a trademark of Eli Lilly and Company.
LILLY INSULINS GENERAL INFORMATION
See Summaries of Product Characteristics for additional information, including time-
action profiles of all formulations.
Dosage and Administration (general) The dosage or type of insulin should be
determined according to the requirements of the patient. The time course of action of
any insulin may vary considerably in different individuals or at different times in the
same individual. Vials are packed with instructions regarding dose preparation and
administration, and these should be carefully followed. Lilly insulin cartridges are to
be used with a CE marked pen according to the instructions provided by the device
manufacturer. Patients should be advised to always keep a spare syringe and vial, or a
spare pen and cartridge. Prefilled Pens are packed with instructions on how to use them.
These directions should be followed carefully. Do not use if, after resuspension, the insulin
remains at the bottom, if there are clumps in the insulin, or if solid white particles stick
to the bottom or wall giving the container a frosted appearance. Contra-indications
Hypersensitivity to the active ingredient or to any of the excipients. Hypoglycaemia.
Warnings and Special Precautions (general) Usage in pregnancy: Insulin
requirements usually fall during the first trimester and increase during the second and
third trimesters. Patients should be advised to inform their doctors if they are pregnant or
contemplating pregnancy. Insulin requirements may be reduced in the presence of renal
impairment or hepatic impairment. However, in patients with chronic hepatic impairment,
an increase in insulin resistance may lead to increased insulin requirements. Insulin
requirements may be increased during illness or emotional disturbances. Transferring a
patient to another type or brand of insulin should be done under strict medical supervision.
Changes in strength, brand, type, species, and/or method of manufacture may result in
the need for a change in dosage. For fast-acting insulins, any patient also on basal insulin
must optimise dosage of both insulins to obtain glucose control across the whole day,
particularly nocturnal/fasting glucose control. Some patients taking human insulin may
require a change in dosage from that used with animal-source insulins. If an adjustment
is needed, it may occur with the first dose or during the first several weeks or months.
Changes in early warning symptoms of hypoglycaemia may occur on transfer between
different types of insulin products. The patient’s ability to concentrate and react may be
impaired as a result of hypoglycaemia. This may constitute a risk in situations where these
abilities are of special importance (eg, driving a car or operating machinery). Treatment
with human insulin may cause formation of antibodies, but titres of antibodies are lower
than those to purified animal insulin. Undesirable Effects Hypoglycaemia is the most
frequent undesirable effect of insulin therapy. Local allergy is common and usually
resolves. Systemic allergy is rare but potentially more serious since severe cases may
be life-threatening. Lipodystrophy is uncommon. For full details of these and other side-
effects, please see the Summary of Product Characteristics, which is available at http://
emc.medicines.org.uk/. Legal Category POM Date of Preparation or Last Review
June 2010 Full Prescribing Information is Available From Eli Lilly and Company
Limited, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL Telephone:
Basingstoke (01256) 315 000 E-mail: ukmedinfo@lilly.com Website: www.lillypro.co.uk
Adverse events should be reported.Reporting forms and information  
can be found at www.yellowcard.gov.uk   Adverse events should also  
be reported to Eli Lilly and Company Limited (Tel No 0870 240 1125).
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